Committee Approves Bill Requiring Warning on Medications With Risks for Drivers

Chamber Approves Warning on Medications That May Impair Driving Ability

The Health Commission of the Chamber of Deputies took an important step for traffic safety by approving a project that requires warnings on the labels, package inserts, and advertising materials of medications capable of affecting the ability to drive.

The measure, which aims to raise consumer awareness about the risks of combining driving and certain medications, was included as a substitute by the rapporteur, Deputy Rogéria Santos (Republicanos-BA), to Bill 877/24, authored by Deputy Juninho do Pneu (União-RJ).

“The use of medications associated with driving can significantly increase the risk of traffic accidents,” stated the rapporteur. She emphasized that the initiative will allow consumers to make safer decisions, reducing the likelihood of accidents.

The proposal amends Law 6.360/76, which regulates health surveillance of medications, expanding the requirements to protect drivers and pedestrians.

The wording of the approved text was carefully adjusted to include the mandatory warnings without excessively burdening the pharmaceutical industry.

The proposal reflects the growing concern for traffic safety, especially in light of frequent reports of accidents associated with the misuse of medications that impair reflexes and attention.

Next Steps in Congress

Now, the project goes for analysis, in a conclusive manner, by the Consumer Defense and Constitution, Justice and Citizenship (CCJ) commissions. If approved in these stages, it will still need to pass a vote in the Chamber and the Senate before being sanctioned and becoming law.

Despite the progress, experts warn that the effectiveness of the measure depends not only on the adoption of the warnings but also on raising public awareness and proper enforcement.

One point that raised questions was the deadline for pharmaceutical companies to adapt to the new requirements, which will still be defined in subsequent regulation. This highlights the importance of open dialogue among government, industry, and society.

With the final approval, it is expected that the initiative will contribute to the reduction of accidents related to the use of medications and driving.

Sign up

Connect with

Access

I allow you to create an account.

When you first accessed our site using a Social Access button, we collected your public profile information shared by the Social Access provider, based on your privacy settings. We also obtained your email address to automatically create an account for you on our website. Once your account is created, you will be logged into that account.

I disagreeI agree

Notify of

new follow-up comments new responses to my comments

Label

Name*

E-mail*

Save my data for the next time I comment.

Save my name, email, and website in this browser's cookies for the next time I comment.

ONESIGNAL ID

ONESIGNAL ID

I allow you to create an account.

When you first accessed our site using a Social Access button, we collected your public profile information shared by the Social Access provider, based on your privacy settings. We also obtained your email address to automatically create an account for you on our website. Once your account is created, you will be logged into that account.

I disagreeI agree

Label

Name*

E-mail*

Save my data for the next time I comment.

Save my name, email, and website in this browser's cookies for the next time I comment.

ONESIGNAL ID

ONESIGNAL ID

0 Comments

most recent

older Most voted